Compare Sumitomo Mitsui Financial Group Inc Unsponsored American Depositary Shares (Japan) (SMFG) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sumitomo Mitsui Financial Group Inc Unsponsored American Depositary Shares (Japan) vs State Street SPDR S&P Biotech ETF — how do they compare? Sumitomo Mitsui Financial Group Inc Unsponsored American Depositary Shares (Japan) trades at $24.99 (market cap $156.97B), while State Street SPDR S&P Biotech ETF trades at $153.56 (market cap $10.11B). The key difference: Sumitomo Mitsui Financial Group Inc Unsponsored American Depositary Shares (Japan) is far larger — about 15.5× State Street SPDR S&P Biotech ETF's market cap, and Sumitomo Mitsui Financial Group Inc Unsponsored American Depositary Shares (Japan) pays a 2.34% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Sumitomo Mitsui Financial Group Inc Unsponsored American Depositary Shares (Japan) for 0 Days and State Street SPDR S&P Biotech ETF for 37 Days on average.
| SMFG | XBI | |
|---|---|---|
Market Cap | $156.97B | $10.11B |
Volume | 1,237,125 | 12,903,266 |
Sector | Financials | Broad Market / Factor |
52-Week High | $27.56 | $169.55 |
52-Week Low | $15.20 | $104.99 |
Typical Hold Time | 0 Days | 37 Days |
Enterprise Value | $12.48T | — |
Dividend Yield | 2.34% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
XBI trades at $153.34, up 2.07% today, but faces bearish technical signals with 17 sell indicators versus 4 buys. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from recent M&A activity and positive clinical trial catalysts. Current price sits near resistance at $154, with support at $147.
Biotech sector optimism is growing with cancer vaccine breakthroughs and improved capital access, though XBI's 0.35% expense ratio is higher than broader healthcare ETFs. Key risks include sector volatility and regulatory uncertainty, while analyst consensus remains neutral with 100% hold rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Sumitomo Mitsui Financial Group Inc Unsponsored American Depositary Shares (Japan)
Sumitomo Mitsui Financial Group is a Japanese financial services company with banking, securities, leasing, and asset management businesses. It serves retail, corporate, and institutional clients.
Read more on SMFG →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
